General Information About Neuroblastoma Cancer
Neuroblastoma is a disease in which malignant (cancer) cells form in nerve tissue.Neuroblastoma often begins in the nerve tissue of the adrenal glands. There are two adrenal glands, one on top of each kidney, in the back of the upper abdomen. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the abdomen, chest, spinal cord, or in nerve tissue near the spine in the neck.Anatomy of the female urinary system showing the kidneys, adrenal glands, ureters, bladder, and urethra. Urine is made in the renal tubules and collects in the renal pelvis of each kidney. The urine flows from the kidneys through the ureters to the bladder. The urine is stored in the bladder until it leaves the body through the urethra.Neuroblastoma most often begins during early childhood, usually in children younger than 5 years of age.See the PDQ summary on Neuroblastoma Treatment for more
Stages of Adult Brain Tumors
There is no standard staging system for adult brain and spinal cord tumors.The extent or spread of cancer is usually described as stages. There is no standard staging system for brain and spinal cord tumors. Brain tumors that begin in the brain may spread to other parts of the brain and spinal cord, but they rarely spread to other parts of the body. Treatment of brain and spinal cord tumors is based the following:The type of cell in which the tumor began.Where the tumor formed in the brain or spinal cord.The amount of cancer left after surgery.The grade of the tumor.Treatment of brain tumors that have spread to the brain from other parts of the body is based on the number of tumors in the brain.Imaging tests may be repeated after surgery to help plan more treatment.Some of the tests and procedures used to diagnose a brain or spinal cord tumor may be repeated after treatment to find out how much tumor is left.
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Brain Stem Glioma Treatment
Treatment Options for Childhood Brain Stem Glioma
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your child's doctor for clinical trials that are not listed here but may be right for your child.Untreated Childhood Brain Stem GliomaUntreated childhood brain stem glioma is a tumor for which no treatment has been given. The child may have received drugs or treatment to relieve symptoms caused by the tumor.Standard treatment of diffuse intrinsic pontine glioma is usually radiation therapy.Some of the treatments being studied in clinical trials for diffuse intrinsic pontine glioma include the following:Radiation therapy with a radiosensitizer.Standard treatment of focal or low-grade glioma may include the following:Surgery with or without radiation therapy, which may be followed by adjuvant chemotherapy.Cerebrospinal fluid diversion followed by watchful waiting.Treatment of brain stem glioma in children with
Changes to This Summary (01 / 30 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Treatment of Recurrent Childhood EpendymomaAdded Bouffet et al. as reference 8.This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Ependymoma Treatment
This cancer treatment information summary provides an overview of the diagnosis,classification,treatment,and prognosis of childhood brain stem gliomas. The National Cancer Institute provides the PDQ pediatric cancer treatment information summaries as a public service to increase the availability of evidence-based cancer information to health professionals,patients,and the public. These ...
Incidence and MortalityAbout 7% of all malignancies in children younger than 15 years are neuroblastomas. About one quarter of cancers in the first year of life are neuroblastomas, making this the most frequent histological type of infant cancer.[1,2] The incidence rate of the disease in children younger than 1 year is about 35 per million but declines rapidly with age to about 1 per million between ages 10 and 14 years. Males appear to be affected slightly more commonly than females, with about five cases occurring in boys to every four occurring in girls. Screening Method and SensitivityThe risk factors for and causes of neuroblastoma have not been established, and therefore it is not possible to provide information or advice for the primary prevention of this disease. It is generally thought that many neuroblastomas are present and detectable at birth, thereby allowing for detection of tumors by a single, once-in-a-lifetime screening test, such as those used for neonatal
Evidence of Benefit
Evidence of screening effect derives from descriptive studies of local and national programs in Japan, uncontrolled pilot experiences at a number of sites in Europe and the United States, and population-based studies in Canada and Germany.[1,2,3,4,5,6,7]An increase in survival rates among screen-detected cases would be expected if screening was detecting neuroblastoma at an earlier and more curable stage. While improved survival rates after initiation of screening have been reported,[8,9] these observations should be viewed cautiously because improvements could be caused by lead-time bias, length bias, and identification of cases through screening that would have spontaneously regressed. Screening results in an increased incidence of early-stage disease. The cases detected by screening almost exclusively have biologically favorable properties (unamplified N-myc oncogene, near triploidy, and favorable histology), and this type of favorable neuroblastoma has a high
Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.